Tagged with R

Biopharmaceuticals Over the past decade since its founding, what are some of the highlights in the transformation of Taiwan Advance Bio-Pharmaceutical Inc. (TABP) into a well established company? TABP was founded in 2000 as a spinoff of the Development Center for Biotechnology (DCB). The DCB was established in 1984 to support…

GCB Mr. Lin, you enjoyed a decades-long career in the ICT industry before making the transition to healthcare. What can you tell our readers about the evolution of General Biologics Corp. under your leadership? GBC was established in 1984. Government shareholders held 70 percent ownership, with the remaining 30 percent distributed…

API Industry Formosa Laboratories is one of Taiwan’s international pioneers in small molecules, entering the global arena at a very early stage. How did that decision come about? Generally speaking, Taiwan’s API industry decided to go global long before the formulation sector did. The reason is simple: the local market for APIs…

APAC Region PAREXEL has been in Asia Pacific (APAC) since the company entered Japan in 1995. It chose Taiwan as its regional base of operations with the 2007 acquisition of APEX, a company you founded in 1999. Today, does Taiwan continue to make sense as PAREXEL’s APAC headquarters? We believe that it…

Industrial Biotech Prior to joining Life Sciences Ontario (LSO), you served as CEO of GSK Canada for a number of years. What opportunities did you see in making the switch from an MNC to an association? Having been in the pharmaceutical business for my entire career in Canada, I have always been…

Burrill & Company The managing director of Burrill & Company discusses the biotech industry in Taiwan, the various hurdles the market faces and why there is so much potential for industry growth in Taiwan. During the six years that you have been with Burrill, you have mostly covered the Greater China region. What…

Array Ask Indonesians about a bad experience in medical care and each will have a story to tell. The poor state of Indonesia’s healthcare system has turned ‘improving quality’ into the top priority of the government of Indonesia. Better quality of care has become especially important as the fourth most populated…

R&D The president of Sanofi Pasteur Canada discusses the greatest challenges currently facing vaccine companies in Canada, and the added value that Canada’s R&D framework brings to a vaccine company like Sanofi Pasteur. What are the greatest challenges of the vaccine industry in Canada today? The biggest challenge is keeping ahead…

Aspen Labs Marked socio-economic differences in Mexico are playing an important role in pushing the uptake of generics, and these issues are starting to affect multinational corporations (MNCs). MNCs are being forced to open up and diversify, quite simply to have their fingers in as many pies where they can compete successfully.…

Dialysis The general manager of Baxter in the Nordic region discusses the concept of home care, and how brand new technologies currently being tested in Sweden should mean that soon, dialysis treatment will shift from the hospital to the home around the world. Could you please give us a brief introduction…

Generics The president & CEO of Canada’s largest generics player considers the current market dynamics for generic products, including IP regulation, generic penetration, and the advantages of balancing branded and non-branded products.  What was the strategy behind the integration of Novopharm into Teva? Novopharm is one of the pioneers in the…

Clinical trials TaiGen is on the brink of releasing Taiwan’s first innovative drug. In this interview, the Chairman and CEO of the company discusses the development path the company chose to take, and explains the decision to market the drug first in China. Nemonoxacin will be the first-ever pharmaceutical developed in this…